Time to Stop Progesterone Receptor Testing in Breast Cancer Management
- 1 May 2004
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (9) , 1769-1770
- https://doi.org/10.1200/jco.2004.99.251
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast CancerJournal of Clinical Oncology, 1999
- Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.Journal of Clinical Oncology, 1996
- Oestrogen and Progesterone Receptors as Prognostic Variables in Hormonally Treated Breast CancerThe International Journal of Biological Markers, 1996
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06.Journal of Clinical Oncology, 1988
- Prognostic significance of oestrogen and progestogen receptor activities in breast cancerBritish Journal of Surgery, 1987